Latest News
Senate Panel Advances Crypto Bill, DeFi Pushback and Stablecoin Issues Remain
The Digital Asset Market Clarity Act passed the Senate Banking Committee 15-9 but faces new opposition from DeFi developers and key Democrats over securities amendments and stablecoin provisions.
Carnival Stock Recovers as Dividend, Fuel Costs and Restructuring Draw Attention
Carnival shares edged higher Wednesday, recovering from Tuesday's decline, as the market evaluates its dividend timeline, recent corporate simplification, and lingering fuel-cost exposure.
Mister Car Wash Exits Nasdaq After $3.1B Take-Private by Leonard Green
Mister Car Wash has been taken private by Leonard Green & Partners in a $3.1 billion deal, ending its Nasdaq listing. Shareholders received $7.00 per share.
T1 Energy Surges on Hedge Fund Stake and Short Seller Allegations
T1 Energy shares surged 17% as a hedge fund disclosed a new stake, while a short-seller report questioned the company's tax-credit eligibility and China-linked supply chain.
POET Technologies Surges 11% After Closing $400M Offering; Revenue Concerns Persist
POET Technologies shares climbed 11% to $14.55 after closing a $400 million direct offering, bouncing back from an 8% drop on dilution concerns. The company reported Q1 revenue of $503,389 and a net loss of $12.3 million.
Nokia Secures FCC Approval for Broadband Devices, Optical Market Poised for Growth
Nokia shares gained 3.37% in Helsinki after the FCC conditionally approved its Beacons and ONT devices. Dell'Oro Group predicts the optical transport equipment market will grow 16% in 2026, fueled by AI data centers.
Biogen Closes Apellis Takeover; Focus Shifts to Syfovre Milestones
Biogen has completed its $5.6 billion acquisition of Apellis Pharmaceuticals, delisting APLS from Nasdaq. Shareholders received $41 per share plus a contingent value right linked to Syfovre sales targets.
Vida CEO Buys $1.19M in Shares After AI IPO Stumbles
Vida Global CEO Lyle Pratt bought $1.19M in shares after the AI firm's $15M IPO fell 42.8%. The stock closed at $2.29, well below the $4 offer price.
TJX Shares Jump After Parent Company Raises Annual Guidance
TJX Companies raised its fiscal 2027 sales, earnings, and buyback targets after a better-than-expected Q1, sending shares up 3.6% premarket.
ImmunityBio's Anktiva Expansion Faces FDA Scrutiny with 2027 Decision Date
ImmunityBio's supplemental BLA for Anktiva in papillary-only bladder cancer has been accepted by the FDA, with a decision expected by Jan. 6, 2027. The company's stock traded at $7.76, down 2.8%.